Cyclophosphamide (CY)

DRUG18 trials

Sponsors

Sidney Kimmel Cancer Center at Thomas Jefferson University, Nanfang Hospital, Southern Medical University, Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI), M.D. Anderson Cancer Center

Conditions

ALLAMLAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Phase 1

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

CompletedNCT00429143

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHematologic Malignancies

Start: 2006-01-31End: 2010-06-30Updated: 2025-05-04

Phase 2

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

CompletedNCT01384513

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAdult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities +44

Start: 2011-08-04End: 2022-11-16Updated: 2022-11-17

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

TerminatedNCT01532635

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, ALL +9

Start: 2012-03-31End: 2013-05-31Updated: 2025-05-04

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

CompletedNCT02671708

Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukemia, Autologous Hematopoietic Stem Cell Transplantation, Conditioning

Start: 2016-01-31End: 2020-02-28Updated: 2020-03-03

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

CompletedNCT02744742

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2016-04-18End: 2021-09-30Updated: 2022-02-14

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Diffuse Large B-cell Lymphoma

Start: 2017-07-05End: 2020-06-30Target: 122Updated: 2017-10-12

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma

Start: 2018-01-02End: 2021-12-31Target: 122Updated: 2020-02-25

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditions, Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

Start: 2018-07-31End: 2022-06-30Target: 122Updated: 2018-07-24

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruitingNCT03674411

Masonic Cancer Center, University of MinnesotaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated Leukemia +8

Start: 2019-01-02End: 2026-12-01Updated: 2026-01-06

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Primary Central Nervous System Lymphoma

Start: 2018-11-30End: 2021-10-31Target: 20Updated: 2018-11-07

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors

Start: 2019-09-30End: 2023-08-31Target: 196Updated: 2019-09-23

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors +1

Start: 2019-10-31End: 2023-09-30Target: 196Updated: 2019-10-10

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2021-01-15End: 2024-07-31Target: 242Updated: 2021-01-19

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

RecruitingNCT05027945

National Cancer Institute (NCI)Hematopoietic Stem Cell Transplantation, Immunodeficiency

Start: 2023-02-23End: 2026-07-01Target: 54Updated: 2026-04-02

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

WithdrawnNCT05293509

M.D. Anderson Cancer CenterStem Cell Transplantation

Start: 2022-03-02End: 2023-09-18Updated: 2023-09-21

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Secondary Acute Myeloid Leukemia Evolving From MDS

Start: 2022-07-31End: 2024-12-31Target: 232Updated: 2022-07-08

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2022-07-01End: 2024-12-31Target: 242Updated: 2023-03-21

Phase 3

BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

CompletedNCT02670252

Nanfang Hospital, Southern Medical UniversityAcute Lymphocytic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan +1

Start: 2016-01-31End: 2022-02-28Updated: 2022-04-08

Related Papers

Sustained donor engraftment and clinical remission after hematopoietic cell transplantation for vexas syndrome, but with observed toxicities: Results from a prospective phase II clinical Trial

Blood2025-11-03

Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome

Blood2023-11-024 citations

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.

2023-01-2319 citations

Idarubicin plus <scp>BuCy</scp> versus <scp>BuCy</scp> conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing <scp>auto‐HSCT</scp>: An open‐label, multicenter, randomized phase 3 trial

American Journal of Hematology2023-01-015 citations

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood2022-11-15

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial

Journal of Clinical Oncology2022-09-0948 citations

Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD)

Biology of Blood and Marrow Transplantation2020-01-23

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Blood2019-11-134 citations

A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing.

2011-08-2558 citations